Hemodialysis reduces plasma apolipoprotein C-I concentration making VLDL a better substrate for lipoprotein lipase

G Dautin1, Z Soltani, D Ducloux

  • 11INSERM U866, Faculté de Médecine, Dijon, France.

Kidney International
|August 2, 2007
PubMed

Insights

Hemodialysis significantly reduces apolipoprotein C-I levels, potentially improving very low-density lipoprotein (VLDL) function and triglyceride metabolism in chronic renal failure patients.

Area of Science:

  • Lipid Metabolism
  • Renal Disease Pathophysiology
  • Biochemistry

Background:

  • Apolipoprotein Cs (apoC-I, apoC-II, apoC-III) are key regulators of lipoprotein metabolism.
  • Low molecular weight apoCs can be removed by dialysis membranes.
  • Chronic renal failure impacts lipoprotein metabolism and enzyme activities.

Purpose of the Study:

  • To investigate the effects of hemodialysis (HD) on plasma concentrations of apoCs.
  • To assess the impact of HD on enzyme activities modulated by apoCs.
  • To determine the clinical significance of apoC changes during HD.

Main Methods:

  • Plasma samples collected from 28 chronic renal failure patients before and after HD.
  • Quantification of apoC-I, apoC-II, and apoC-III levels.
  • Assays for very low-density lipoprotein (VLDL) and high-density lipoprotein (HDL) associated apoCs.
  • Evaluation of VLDL interaction with cholesterol ester transfer protein and lipoprotein lipase (LPL).

Main Results:

  • Plasma apoC-II levels remained unchanged post-HD.
  • Plasma apoC-III levels showed a slight decrease after HD.
  • Significant reduction in plasma apoC-I, primarily from VLDL, was observed.
  • Post-HD VLDL showed enhanced LPL substrate activity, but no change in CETP interaction.

Conclusions:

  • Hemodialysis leads to a significant loss of apoC-I from VLDL.
  • This loss may improve VLDL's ability to act as an LPL substrate.
  • ApoC-I reduction during HD could be beneficial for triglyceride metabolism in renal patients.

Related Concept Videos

Hemodialysis I: Introduction01:25

Hemodialysis I: Introduction

Hemodialysis (HD) is a medical treatment that artificially removes waste products, excess fluids, and toxins from the blood when the kidneys are no longer able to perform these functions effectively. In this process, blood is filtered through a semipermeable membrane, allowing for the selective removal of waste while preserving necessary components like blood cells and proteins. Hemodialysis is typically performed in patients with end-stage renal disease (ESRD) or severe kidney...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Dialysis01:15

Dialysis

Dialysis is a diffusion-based purification process that separates analyte molecules from a complex matrix. This is accomplished by allowing molecules in the solution to pass through a semipermeable membrane into a liquid on the other side. The membrane is usually made of cellulose acetate or cellulose nitrate, and the second liquid must be miscible with the solution. Ions (e.g., chloride or sodium) or organic molecules (e.g., glucose) can pass through the membrane pores, which generally have...
Dialysis01:27

Dialysis

Renal failure occurs when the kidneys lose their ability to filter waste products from the blood effectively. It can be classified into two types: acute renal failure (ARF) and chronic renal failure (CRF).
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
Hemodialysis II: Procedure and Complications01:24

Hemodialysis II: Procedure and Complications

DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...